nCage Technology

Antibody Drug Conjugates (ADCs) are oncology drugs which, unlike chemotherapy, target cancer cells and spare healthy ones.

As a result, they are emerging as the main type of cancer treatment.

However, they face difficult challenges:

• Extremely high prevalence of adverse side effects.

• High ADC clinical trial failure rate.

Despite safety concerns, the ADC pipeline remains strong, but a solution to improve safety is still needed.

0.1%

Of the injected dose of an ADC finds its way to the targeted diseased cell population.

46%

Of patients experience severe side effects.

nCage have the potential to address the safety problem of ADCs

Safety problem in ADC's

Antibody Drug Conjugates (ADCs)

Toxic drug molecules are presented on the outside and can be easily detached from the antibody.

Systemically administered ADCs are widely distributed in the body. When toxic payloads detach from the antibody, they can bind off-target and have unwanted side effects.

Solution developed by nCage

TRAP Cage Conjugates (TCCs)

Toxic drug molecules are locked inside the cage and can be detached only in specific predetermined conditions.

Systemic distribution of TCCs should result in fewer side effects as the drug is not released from the cage until it reaches the target.

TRAP Cage Conjugates

However, they face difficult challenges:

0.1%

46%

Best Selling ADCs in 2021

nCage have the potential to address the safety problem of ADCs

Antibody Drug Conjugates (ADCs)

TRAP Cage Conjugates (TCCs)